Androvia Release: Three Studies Conveying Benefits Of New Male Fertility Assay To Be Presented At Scientific Congress of the American Society for Reproductive Medicine
MOUNTAINSIDE, N.J., Oct. 6, 2016 /PRNewswire/ -- Androvia LifeSciences, a biotechnology company engineering solutions for the advancement of male fertility, today announced that data related to the company's proprietary technology, the Cap-Score Sperm Function Test, will be presented in three poster sessions at the 72nd Annual American Society for Reproductive Medicine Scientific Congress & Expo (ASRM), to be held October 15 19, 2016 in Salt Lake City, Utah.
"Because this new assay is able to help clinicians determine the specific fertility treatment that is most suitable for each couple, it is inherently able to reduce overall costs while increasing the pregnancy rate," said Joseph B. Babigumira, PhD, Departments of Pharmacy and Global Health, University of Washington, who led the study being presented at ASRM exploring the reduction in medical costs associated with use of the Cap-Score Sperm Function Test.
The studies related to Cap-Score that are being presented at the ASRM annual conference this year consist of:
Capacitation defects are common in men questioning their fertility and are independent of standard semen analysis parameters
- Poster # P-354
- Poster session: Tuesday, October 18, 2016 from 7 a.m. 8:45 a.m. MDT
- Lead author: Alexander J. Travis, PhD, associate professor, Cornell University and chief scientific officer, Androvia LifeSciences
Potential Impact of the Cap-Score test on clinical pregnancy and medical costs in couples with unexplained infertility
- Poster # P-512
- Poster session: Wednesday, October 19, 2016 from 7 a.m. 8:45 a.m. MDT
- Lead author: Joseph B. Babigumira, PhD, Departments of Pharmacy and Global Health, University of Washington
Capacitation timing varies among men, but is consistent among ejaculates within individuals
- Poster # P-523
- Poster session: Wednesday, October 19, 2016 from 7 a.m. 8:45 a.m. MDT
- Lead author: Alexander J. Travis, PhD, associate professor, Cornell University and chief scientific officer, Androvia LifeSciences
Abstracts summarizing these data are available on the ASRM website at: http://scientific.asrmcongress.org/Portals/1/2016PDFs/2016AbstractSupplement.pdf?ver=2016-09-09-093055-120
About Cap-Score Sperm Function Test
A laboratory developed test designed to assess and measure the fertilizing ability of sperm, to help couples and reproductive health care professionals make informed decisions about the fertility solution that is best suited for that couple. The Cap-Score Sperm Function Test provides an analysis of the sperm on a molecular level, and is the only assay that evaluates capacitation, the process by which sperm acquire the ability to fertilize an egg. The test is being designed to complement the traditional semen analysis which determines sperm count, motility and appearance.
About Androvia LifeSciences
Androvia LifeSciences is a biotechnology company focused on engineering scientific technology for the advancement of male fertility, and empowering men with the information to help determine personalized fertility solutions. It is among only a few companies in the world focused on male fertility today.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/three-studies-conveying-benefits-of-new-male-fertility-assay-to-be-presented-at-scientific-congress-of-the-american-society-for-reproductive-medicine-asrm-300340684.html
SOURCE Androvia LifeSciences
